What if you invested $1000 in AZN on Jan 1, 2020?
Explore hypothetical investment results for stocks, ETFs, and more. See real historical data and share your discoveries.
Historical Annual Returns
Over the past 20 years, AstraZeneca plc has delivered an average annual return of 11.4%. The stock peaked in 2025 with a massive +42.5% gain, while investors faced a downturn in 2007 (-18.0%). Overall, the stock finished in the green 16 times out of 20 years.
Avg Return
+11.4%
Win Rate
80%
16W - 4L
Best
+42.5%
2025
Worst
-18.0%
2007
Performance Consistency
About AstraZeneca plc
Visit Website ↗AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines in Oncology, Rare Disease and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Key Business Segments
Oncology
Focuses on developing medicines for various types of cancer.
Rare Disease
Develops treatments for a range of rare diseases.
BioPharmaceuticals
Includes medicines for cardiovascular, renal & metabolism, and respiratory & immunology diseases.
Key Innovations
- ✓Development of Xylocaine (lidocaine), a widely used local anesthetic.
- ✓Significant contributions to cardiovascular and respiratory medicines.
- ✓Development of a COVID-19 vaccine in collaboration with the University of Oxford.
Historical Milestones
AstraZeneca plc is formed through the merger of Astra AB (Sweden) and Zeneca Group PLC (UK).
Acquires MedImmune, significantly expanding its biologics capabilities.
Acquires Alexion Pharmaceuticals Inc., marking its entry into rare disease medicines.